Head to Head Analysis: Embecta (NASDAQ:EMBC) vs. bioMerieux (OTCMKTS:BMXMF)

bioMerieux (OTCMKTS:BMXMF) and Embecta (NASDAQ:EMBC) are both healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their dividends, analyst recommendations, risk, earnings, profitability, institutional ownership and valuation.

Risk & Volatility

bioMerieux has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Comparatively, Embecta has a beta of 0.81, suggesting that its share price is 19% less volatile than the S&P 500.

Valuation & Earnings

This table compares bioMerieux and Embecta”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioMerieux	$4.60 billion	2.03	$449.73 million	N/A	N/A
Embecta	$1.08 billion	0.21	$95.40 million	$1.90	2.01

bioMerieux has higher revenue and earnings than Embecta.

Insider & Institutional Ownership

93.8% of Embecta shares are held by institutional investors. 1.3% of Embecta shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Profitability

This table compares bioMerieux and Embecta’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
bioMerieux	N/A	N/A	N/A
Embecta	10.73%	-23.96%	14.12%

Analyst Ratings

This is a summary of recent recommendations for bioMerieux and Embecta, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioMerieux	2	4	0	0	1.67
Embecta	2	3	0	0	1.60

Embecta has a consensus target price of $11.00, indicating a potential upside of 187.96%. Given Embecta’s higher possible upside, analysts clearly believe Embecta is more favorable than bioMerieux.

Summary

Embecta beats bioMerieux on 6 of the 11 factors compared between the two stocks.

About bioMerieux

bioMérieux S.A. develops and produces in vitro diagnostic solutions for the diagnosis of infectious diseases in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. The company offers systems that use biological samples, such as blood, saliva, urine, etc. for the diagnosis of infectious diseases, including bacterial infections, parasitic infections, and viral infections; and microbiological control of production or the production environment primarily for food, pharmaceutical, and cosmetic industries. It also provides a suite of software products and services that collect, analyze, and merge various sources of data to make decisions under the BIOMÉRIEUX VISION SUITE name; designs, manufactures, and maintains instruments and software; and designs and manufactures reagents for in vitro diagnostic tests. The company serves clinical and hospital laboratories, physicians, blood banks, vets, and industrial control laboratories. bioMérieux S.A. was formerly known as B-D Mérieux. The company was founded in 1963 and is headquartered in Marcy-l'Étoile, France. bioMérieux S.A. is a subsidiary of Institut Mérieux SA.

About Embecta

Embecta Corp., a medical device company, focuses on the provision of various solutions to enhance the health and wellbeing of people living with diabetes. Its products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes. The company primarily sells its products to wholesalers and distributors in the United States and internationally. Embecta Corp. was founded in 1924 and is headquartered in Parsippany, New Jersey.